The Medicare hospital outpatient rate for the Argus II retinal prosthesis system has been set at $152,500 by CMS, Second Sight Medical Products announced in a press release.
Argus II is the only FDA- and CE mark-approved device for the treatment of retinitis pigmentosa.
“We are delighted to have received CMS’ final 2019 outpatient payment rate, which provides Medicare patients continued access to our life-changing technology,” Will McGuire, Second Sight CEO and president, said in the release. “We are also happy to see the change in methodology that considers multiple years of historic data when setting a rate for a low-volume device such as Argus. We believe this change will temper future year-to-year fluctuations in the reimbursement rate.”